131 related articles for article (PubMed ID: 18981571)
1. Ameliorative effect of Captopril and Valsartan on an animal model of diabetic cardiomyopathy.
Zhang CH; Lu J; Yu XJ; Sun L; Zang WJ
Biol Pharm Bull; 2008 Nov; 31(11):2045-9. PubMed ID: 18981571
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. [The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice].
Xie XW; Zhao P
Zhonghua Yan Ke Za Zhi; 2004 Nov; 40(11):770-3. PubMed ID: 15634486
[TBL] [Abstract][Full Text] [Related]
4. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
[TBL] [Abstract][Full Text] [Related]
6. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
Maggioni AP; Fabbri G
Expert Opin Pharmacother; 2005 Mar; 6(3):507-12. PubMed ID: 15794740
[TBL] [Abstract][Full Text] [Related]
7. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Yano H; Hibi K; Nozawa N; Ozaki H; Kusama I; Ebina T; Kosuge M; Tsukahara K; Okuda J; Morita S; Umemura S; Kimura K
Circ J; 2012; 76(6):1442-51. PubMed ID: 22473458
[TBL] [Abstract][Full Text] [Related]
8. Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus.
Yang ZH; Peng XD
Chin Med J (Engl); 2010 Dec; 123(24):3640-3. PubMed ID: 22166644
[TBL] [Abstract][Full Text] [Related]
9. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of renin-angiotensin system in experimental acute pancreatitis in rats: a new therapeutic target?
Oruc N; Ozutemiz O; Nart D; Yuce G; Celik HA; Ilter T
Exp Toxicol Pathol; 2010 Jul; 62(4):353-60. PubMed ID: 19525099
[TBL] [Abstract][Full Text] [Related]
11. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
Pfeffer MA; McMurray J; Leizorovicz A; Maggioni AP; Rouleau JL; Van De Werf F; Henis M; Neuhart E; Gallo P; Edwards S; Sellers MA; Velazquez E; Califf R
Am Heart J; 2000 Nov; 140(5):727-50. PubMed ID: 11054617
[TBL] [Abstract][Full Text] [Related]
12. From black and white to shades of gray: race and renin-angiotensin system blockade.
Havranek EP
J Am Coll Cardiol; 2008 May; 51(19):1872-3. PubMed ID: 18466802
[No Abstract] [Full Text] [Related]
13. Valsartan, captopril, or both in myocardial infarction.
McAnulty JH
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14985495
[No Abstract] [Full Text] [Related]
14. Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor.
Thomas CM; Yong QC; Seqqat R; Chandel N; Feldman DL; Baker KM; Kumar R
Clin Sci (Lond); 2013 Apr; 124(8):529-41. PubMed ID: 23116220
[TBL] [Abstract][Full Text] [Related]
15. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors.
Yong QC; Thomas CM; Seqqat R; Chandel N; Baker KM; Kumar R
Cardiovasc Diabetol; 2013 Nov; 12():169. PubMed ID: 24215514
[TBL] [Abstract][Full Text] [Related]
17. Valsartan protects against ER stress-induced myocardial apoptosis via CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats.
Wu T; Dong Z; Geng J; Sun Y; Liu G; Kang W; Zhang Y; Ge Z
Eur J Pharm Sci; 2011 Apr; 42(5):496-502. PubMed ID: 21345370
[TBL] [Abstract][Full Text] [Related]
18. Valsartan, captopril, or both in myocardial infarction.
Jorde UP
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
[No Abstract] [Full Text] [Related]
19. Valsartan, captopril, or both in myocardial infarction.
Moshenyat R; Kupfer Y; Tessler S
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988935
[No Abstract] [Full Text] [Related]
20. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME
Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
